Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743583 | 0.85 | KDR (0.43) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL29693646 | 0.83 | NPC1 (0.55) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL29948971 | 0.83 | NPC1 (0.55) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL1923392 | 0.83 | NPC1 (0.55) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL29948741 | 0.83 | NPC1 (0.55) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL30435330 | 0.83 | LMNA (0.42) | ALDH1A1NPC1KMT2AMEN1MAPT | |
| SCHEMBL29036570 | 0.83 | LMNA (0.42) | ALDH1A1NPC1KMT2AMEN1MAPT | |
| SCHEMBL5743156 | 0.78 | LMNA (0.42) | NPC1KMT2AMEN1MAPTLMNA | |
| SCHEMBL8299614 | 0.77 | ALDH1A1 (0.46) | ALDH1A1NPC1KMT2AMEN1HTT | |
| SCHEMBL8299821 | 0.77 | SMN1; SMN2 (0.47) | ALDH1A1NPC1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925076-A | Nevirapine intermediate compound and preparation method and application thereof | 山东新时代药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116813538-A | Nevirapine intermediate compound and preparation method thereof | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116410129-A | Nevirapine intermediate compound | 山东新时代药业有限公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-1655300-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1294720-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-04-05 | — | — | EP | disclosed |
| EP-1294720-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-03-26 | — | — | EP | disclosed |
| US-6420359-B1 | 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
| WO-2001096338-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | ALDH1A1 1770/4885NPC1 962/4885KMT2A 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.